A reversible case of pulmonary hypertension in a patient treated with the tyrosine kinase inhibitor bosutinib for chronic myeloid leukemia
Abstract
BCR/ABL1-specific tyrosine kinase inhibitors, which are widely used in the treatment of chronic myeloid leukemia, are known to have numerous cardiovascular side effects. These include precapillary pulmonary hypertension. Such adverse effects may be potentially reversible with dose reduction, discontinuation of therapy, or switching to another tyrosine kinase inhibitor; therefore, early identification of side effects is particularly important. Beyond this recognition, the value of our case lies in the diagnosis of pulmonary hypertension confirmed by Swan–Ganz catheterization, the rapid clinical improvement following discontinuation of the tyrosine kinase inhibitor, and the normalization of pulmonary pressures.
References
Lyon AR, López-Fernándes T, Couch LS és mtsai: 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS): De-veloped by the task force on cardio-oncology of the European Society of Cardiology (ESC). Eur Heart J 2022; 43: 4229-4361. https://academic.oup.com/eurheartj/article/43/41/4229/6673995?login=true
Cortes JE, Saglio G, Kantajiran HM és mtsai: Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naďve Chronic Myeloid Leukemia Patients Trial. J Clin Oncol 2016; 34: 2333-2340. https://doi.org/10.1200/JCO.2015.64.8899
Abu Rmilah AA, Lin G, Begna KH és mtsai: Risk of QTc prolongation among cancer patients treated with tyrosine kinase inhibitors. Int J Cancer 2020; 147: 3160-3167. https://doi.org/10.1002/ijc.33119
El-Dabh A, Acharya D: Pulmonary hypertension with dasatinib and other tyrosine kinase inhibitors. Pulm Circ 2019. 9: 2045894019865704. https://doi.org/10.1177/2045894019865704
Brümmendorf TH, Cortes JE, Milojkovic D és mtsai: Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial. Leukemia 2022; 36: 1825-1833. https://doi.org/10.1038/s41375-022-01589-y
Cortes JE, Kantarijan HM, Mauro MJ és mtsai: Long-term cardiac, vascular, hypertension, and effusion safety of bosutinib in patients with Philadelphia chromosome-positive leukemia resistant or intolerant to prior therapy. Eur J Haematol 2021; 106: 808-820. https://doi.org/10.1111/ejh.13608
Cortes JE, Kim D-W, Pinilla-Ibarz J és mtsai: Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial. Blood 2018; 132: 393-404. https://doi.org/10.1182/blood-2016-09-739086
Copyright (c) 2026 Authors
This work is licensed under a Creative Commons Attribution 4.0 International License.
